Serial No. 10/081,711 April 2003

IN THE CLAIMS

A complete set of claims is contained herein. Kindly replace the claims in the application with those contained herein as follows:

1. (Currently amended) A <u>biodegradable</u> device for providing sustained vasodilation at a graft site in within a patient, comprising:

a biocompatible, <u>biodegradable</u> carrier <u>sized to circumferentially</u> <u>encompass said site;</u>

a vasodilator incorporated into said carrier, which vasodilator is present in a topically effective amount to achieve sustained vasodilation at [a selected] <u>said</u> site in a patient.

- 2. (Original) The device of claim 1, wherein said vasodilator is selected from the group consisting of nitroglycerine and calcium channel blockers.
- 3. (Original) The device of claim 2, wherein said calcium channel blockers are selected from the group consisting of: verapamil, diltiazem, and nifedipine.
- 4. (Original) The device of claim 1, wherein said vasodilator comprises a calcium channel blocker and is incorporated into said carrier at a concentration of about 5 mg/2 ml of solution.
- 5. (Original) The device of claim 4, wherein said calcium channel blocker is verapamil.
- 6. (Original) The device of claim 1, wherein said vasodilator is nitroglycerine and is incorporated into said carrier at a concentration of about 1 mg/ml of solution.

Serial No. 10/081,711 April 2003

- 7. (Original) The device of claim 1, wherein said carrier comprises methylcellulose.
- 8. (Original) The device of claim 1, wherein said carrier comprises equine collagen.
- 9. (Original) The device of claim 1, wherein said carrier is in the form of a strip.
- 10. (Original) The device of claim 1, wherein said device is disposed in a sterile container.
- 11. (Original) The device of claim 1, wherein said vasodilation is sustained for several days.
- 12. (Cancel)
- 13. (Currently amended) A method for providing sustained vasodilation at a selected graft site in within a patient, comprising:

administering, at [a] <u>said</u> selected site in a patient, a vasodilator incorporated into a biocompatible, <u>biodegradable</u> carrier <u>sized to</u> <u>circumferentially encompass said site</u>, which vasodilator is present in a topically effective amount to achieve sustained vasodilation at said selected site.

- 14. (Original) The method of claim 13, wherein said vasodilator is selected from the group consisting of nitroglycerine and calcium channel blockers.
- 15. (Original) The method of claim 14, wherein said calcium channel blockers are selected from the group consisting of: verapamil, diltiazem, and nifedipine.
- 16. (Original) The method of claim 13, wherein said vasodilator is a calcium channel blocker and is incorporated into said carrier at a concentration of about 5 mg/2 ml of solution.

Serial No. 10/081,711 April 2003

17.	(Original)	The method of claim 16, wherein said calcium channel blocker is
	verapamil.	

- 18. (Original) The method of claim 13, wherein said vasodilator comprises nitroglycerine, and is incorporated into said carrier at a concentration of about 1 mg/ml of solution.
- 19. (Original) The method of claim 13, wherein said carrier comprises methylcellulose.
- 20. (Original) The method of claim 13, wherein said carrier comprises equine collagen.
- 21. (Original) The method of claim 13, wherein said carrier is in the form of a strip.
- 22. (Original) The method of claim 13, wherein said vasodilation is sustained for several days.
- 23. (Cancel).
- 24. (New) The device of claim 1, wherein said carrier is perforated.
- 25. (New) The method of claim 13, wherein said carrier is perforated.